Search - tctmd.com

Displaying 821 - 840 of 2157

Sort: Relevancy | Date

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Bulimia May Contribute to Premature CVD in Women

L.A. McKeown

October 18, 2019

News Daily News

CMS Cuts to Office-Based Noninvasive Cardiac Tests Are Driving Costs Higher

L.A. McKeown

October 17, 2019

News Daily News

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

L.A. McKeown

October 15, 2019

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Conference News TCT 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

L.A. McKeown

October 09, 2019

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

News Conference News TCT 2019

Robotics and Augmented Reality Show Promise for Improving Access to Care, Reducing Patient Anxiety

L.A. McKeown

September 25, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News CV Team Pro

The Providence St. Vincent Medical Center Cath Lab Team

L.A. McKeown

September 12, 2019

Advertisement

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Bulimia May Contribute to Premature CVD in Women

CMS Cuts to Office-Based Noninvasive Cardiac Tests Are Driving Costs Higher

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Robotics and Augmented Reality Show Promise for Improving Access to Care, Reducing Patient Anxiety

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

The Providence St. Vincent Medical Center Cath Lab Team

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content